BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 1873592)

  • 21. Unrelated donor marrow transplantation in children.
    Balduzzi A; Gooley T; Anasetti C; Sanders JE; Martin PJ; Petersdorf EW; Appelbaum FR; Buckner CD; Matthews D; Storb R; Sullivan KM; Hansen JA
    Blood; 1995 Oct; 86(8):3247-56. PubMed ID: 7579422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
    Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
    Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of graft vs host disease in allogeneic bone marrow transplantation in a single center study from Turkey.
    Ilhan O; Akan H; Koç H; Gürman G; Arslan O; Ozcan M; Erdi H; Erdem C; Konuk N; Uysal A; Beksaç M
    Hematol Cell Ther; 1997 Jun; 39(3):133-6. PubMed ID: 9262989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia.
    Weaver CH; Clift RA; Deeg HJ; Storb R; Appelbaum FR; Bensinger W; Doney K; Hansen JA; Martin PO; Sanders J
    Bone Marrow Transplant; 1994 Dec; 14(6):885-93. PubMed ID: 7711667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors affecting leukemia relapse after allogeneic BMT conditioned with cyclophosphamide and fractionated TBI.
    Zapatero A; Martín de Vidales C; Pinar B; Rodríguez F; Marín A; Cerezo L; Domínguez P; Pérez Torrubia A
    Bone Marrow Transplant; 1996 Sep; 18(3):591-6. PubMed ID: 8879623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
    Soiffer RJ; Fairclough D; Robertson M; Alyea E; Anderson K; Freedman A; Bartlett-Pandite L; Fisher D; Schlossman RL; Stone R; Murray C; Freeman A; Marcus K; Mauch P; Nadler L; Ritz J
    Blood; 1997 Apr; 89(8):3039-47. PubMed ID: 9108425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?
    Ringdén O; Horowitz MM; Sondel P; Gale RP; Biggs JC; Champlin RE; Deeg HJ; Dicke K; Masaoka T; Powles RL
    Blood; 1993 Feb; 81(4):1094-101. PubMed ID: 8427991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
    Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
    Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients.
    Mehta J; Singhal S; Gee AP; Chiang KY; Godder K; Rhee Fv Fv; DeRienzo S; O'Neal W; Lamb L; Henslee-Downey PJ
    Bone Marrow Transplant; 2004 Feb; 33(4):389-96. PubMed ID: 14716338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of methotrexate on relapse after bone-marrow transplantation for acute lymphoblastic leukaemia. International Bone Marrow Transplant Registry.
    Lancet; 1989 Mar; 1(8637):535-7. PubMed ID: 2564066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants.
    Al-Kasim FA; Thornley I; Rolland M; Lau W; Tsang R; Freedman MH; Saunders EF; Calderwood S; Doyle JJ
    Br J Haematol; 2002 Feb; 116(2):483-90. PubMed ID: 11841456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
    Doney K; Hägglund H; Leisenring W; Chauncey T; Appelbaum FR; Storb R
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):472-81. PubMed ID: 12869961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partially mismatched related-donor bone marrow transplantation for pediatric patients with acute leukemia: younger donors and absence of peripheral blasts improve outcome.
    Godder KT; Hazlett LJ; Abhyankar SH; Chiang KY; Christiansen NP; Bridges KD; Lee CG; Geier SS; Goon-Johnson KS; Gee AP; Pati AR; Parrish RS; Henslee-Downey PJ
    J Clin Oncol; 2000 May; 18(9):1856-66. PubMed ID: 10784626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matched-pair analysis comparing allogeneic PBPCT and BMT from HLA-identical relatives in childhood acute lymphoblastic leukemia.
    Vicent MG; Madero L; Ortega JJ; Martinez A; Gomez P; Verdeguer A; Badell I; Muñoz A; Olive T; Maldonado MS; Bureo E; Cubells J; Diaz MA;
    Bone Marrow Transplant; 2002 Jul; 30(1):9-13. PubMed ID: 12105771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire.
    Mohty M; Labopin M; Balère ML; Socié G; Milpied N; Tabrizi R; Ifrah N; Hicheri Y; Dhedin N; Michallet M; Buzyn A; Cahn JY; Bourhis JH; Blaise D; Raffoux C; Espérou H; Yakoub-Agha I
    Leukemia; 2010 Nov; 24(11):1867-74. PubMed ID: 20882046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate.
    Nash RA; Pepe MS; Storb R; Longton G; Pettinger M; Anasetti C; Appelbaum FR; Bowden RA; Deeg HJ; Doney K
    Blood; 1992 Oct; 80(7):1838-45. PubMed ID: 1391947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group.
    Morishima Y; Morishita Y; Tanimoto M; Ohno R; Saito H; Horibe K; Hamajima N; Naito K; Yamada K; Yokomaku S
    Blood; 1989 Nov; 74(6):2252-6. PubMed ID: 2804362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.